You are here

Cynvenio and Saint Luke’s Cancer Institute Launch Pilot Study to Evaluate the Potential for Early Detection of Recurrent Breast Cancer Following Therapy

Cynvenio Biosystems, Inc., a leader in liquid biopsy technology for cancer research and personalized medicine, today announced the launch of a new breast cancer monitoring study in partnership with Saint Luke’s Cancer Institute in Kansas City, Missouri.

Read the full story.

Learn more about Saint Luke's Cancer Institute.